Myocardial perfusion reserve in patients with chronic hepatitis C before and after direct-acting antiviral treatment—a pilot study
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Myocardial perfusion reserve in patients with chronic hepatitis C before and after direct-acting antiviral treatment—a pilot study. / Sølund, Christina; Hasbak, Philip; Knudsen, Andreas; Kjaer, Andreas; Lebech, Anne M.; Weis, Nina.
In: Clinical Physiology and Functional Imaging, Vol. 42, No. 6, 2022, p. 389-395.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Myocardial perfusion reserve in patients with chronic hepatitis C before and after direct-acting antiviral treatment—a pilot study
AU - Sølund, Christina
AU - Hasbak, Philip
AU - Knudsen, Andreas
AU - Kjaer, Andreas
AU - Lebech, Anne M.
AU - Weis, Nina
N1 - Publisher Copyright: © 2022 The Authors. Clinical Physiology and Functional Imaging published by John Wiley & Sons Ltd on behalf of Scandinavian Society of Clinical Physiology and Nuclear Medicine.
PY - 2022
Y1 - 2022
N2 - Introduction: Patients with chronic hepatitis C (CHC) have an increased risk of atherosclerotic cardiovascular disease which may be due to inflammation and endothelial dysfunction caused by the chronic infection. In this prospective pilot study, we assessed, for the first time among patients with CHC the myocardial perfusion reserve (MPR) by Rubidium-82 (82Rb) positron emission tomography (PET)/computed tomography (CT) before and after direct-acting antiviral (DAA) treatment and compared them with biomarkers of systemic inflammation and endothelial dysfunction. Methods: We included 10 patients with CHC who received 8 or 12 weeks of DAA treatment. To obtain the MPR, a cardiac 82Rb PET/CT scan at rest and adenosine-induced stress was performed at baseline and between 12 and 24 weeks post DAA treatment. Additionally, markers of endothelial dysfunction and inflammation were measured at baseline and 12 weeks after DAA treatment. Results: All 10 patients achieved cure and the median age was 50 (range: 40–62 years). The median MPR before treatment was 3.1 (range: 2.3–4.8) compared to 2.9 (range: 2.2–4.1) after DAA treatment p = 0.63. Also, cure after DAA treatment was not associated with an overall significant decrease in markers of endothelial dysfunction and inflammation. Discussion: Cure after DAA treatment in patients with CHC did not improve coronary microvascular function nor did it lead to a decrease in soluble markers of cardiovascular risk in the given time frame where the patients were followed. It should be noted, that MPR before DAA treatment was in the normal range. Considering the small sample size and short follow-up time, further studies are warranted to determine if viral clearance has an effect on coronary microvascular function and endothelial dysfunction.
AB - Introduction: Patients with chronic hepatitis C (CHC) have an increased risk of atherosclerotic cardiovascular disease which may be due to inflammation and endothelial dysfunction caused by the chronic infection. In this prospective pilot study, we assessed, for the first time among patients with CHC the myocardial perfusion reserve (MPR) by Rubidium-82 (82Rb) positron emission tomography (PET)/computed tomography (CT) before and after direct-acting antiviral (DAA) treatment and compared them with biomarkers of systemic inflammation and endothelial dysfunction. Methods: We included 10 patients with CHC who received 8 or 12 weeks of DAA treatment. To obtain the MPR, a cardiac 82Rb PET/CT scan at rest and adenosine-induced stress was performed at baseline and between 12 and 24 weeks post DAA treatment. Additionally, markers of endothelial dysfunction and inflammation were measured at baseline and 12 weeks after DAA treatment. Results: All 10 patients achieved cure and the median age was 50 (range: 40–62 years). The median MPR before treatment was 3.1 (range: 2.3–4.8) compared to 2.9 (range: 2.2–4.1) after DAA treatment p = 0.63. Also, cure after DAA treatment was not associated with an overall significant decrease in markers of endothelial dysfunction and inflammation. Discussion: Cure after DAA treatment in patients with CHC did not improve coronary microvascular function nor did it lead to a decrease in soluble markers of cardiovascular risk in the given time frame where the patients were followed. It should be noted, that MPR before DAA treatment was in the normal range. Considering the small sample size and short follow-up time, further studies are warranted to determine if viral clearance has an effect on coronary microvascular function and endothelial dysfunction.
KW - Rb PET/CT
KW - Rubidium positron emission tomography/computed tomography
KW - DAA treatment
KW - endothelial markers
KW - hepatitis C virus
KW - MPR
U2 - 10.1111/cpf.12772
DO - 10.1111/cpf.12772
M3 - Journal article
C2 - 35766035
AN - SCOPUS:85134950375
VL - 42
SP - 389
EP - 395
JO - Clinical Physiology and Functional Imaging
JF - Clinical Physiology and Functional Imaging
SN - 1475-0961
IS - 6
ER -
ID: 321836974